Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 29

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 29
---
enting Shareholder may only dissent with respect to all the Common Shares held on behalf of any one beneficial owner and registered in the name of the Dissenting Shareholder. Note that Chapter XIV – Division I of
the QBCA, the text of which is attached as Annex C to this Circular and Proxy Statement, sets forth special provisions which are required to be followed with respect to the exercise of Dissent Rights by Beneficial Shareholders (or non-registered Shareholders).

Regulatory Approvals

No material federal, state or provincial regulatory approvals, filings or notices are required under the Agreement in connection with the
Arrangement.

Interests of the Company’s Directors and Executive Officers

In considering the recommendation of the Board to vote “FOR” the Arrangement Resolution and the Compensation Resolution,
Shareholders should be aware that certain directors and executive officers of the Company have interests in the Arrangement that are different from, and/or in addition to, the interests of Shareholders generally. In particular, certain directors and
executive officers are entitled to “collateral benefit” (as defined in MI 61-101) in connection with the transaction (see “Interests of the Company’s Directors and Executive Officers in the Arrangement — Canadian Securities Law Matters”). Additionally, these interests include indemnification of our directors and executive officers following the completion of the Arrangement. The Board was aware of and
considered these interests, among other matters, in reaching its decision to approve the Arrangement and the Agreement.

11

As of the close of business on November 21, 2025, the Record Date, the directors and
officers of the Company held and are entitled to vote, in the aggregate, 5,821,334 Common Shares representing 13.3% of the outstanding Common Shares. See “Security Ownership of Certain Beneficial Owners and Management.”

Voting and Support Agreements

On
November 14, 2025, the directors and executive officers of the Company entered into the Voting and Support Agreements with the Purchaser. The Voting and Support Agreements set forth, among other things, the agreements of such Shareholders to
vote their Common Shares, Options and any other securities convertible into or exchangeable or exercisable for Common Shares, or any other rights to acquire Common Shares (collectively, “Subject Securities”), in favour of the
approval of the Arrangement Resolution, the Liquidation Resolution, the Liquidator Resolution and any proposal to adjourn or postpone the Special Meeting.

Further, on November 20,